Phio Pharmaceuticals Corp. (PHIO)
$
1.3
+0.01 (0.77%)
Key metrics
Financial statements
Free cash flow per share
-7.5937
Market cap
6.2 Million
Price to sales ratio
205.4046
Debt to equity
0
Current ratio
6.3808
Income quality
1.0133
Average inventory
0
ROE
-1.3457
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Phio Pharmaceuticals Corp. develops innovative immuno-oncology therapeutics in the United States, focusing on harnessing the immune system to combat cancer. The company offers the INTASYL therapeutic platform, which targets tumor and immune cells through the regulation of immune system genes. In its pipeline, Phio Pharmaceuticals is developing PH-762, which activates immune cells to identify and destroy cancerous cells by lowering the expression of the checkpoint protein PD-1 for immunotherapy in adoptive cell transfer (ACT). Additionally, PH-894 is designed to silence the epigenetic protein BRD4, functioning as an intracellular gene expression regulator to enhance ACT outcomes. Furthermore, PH-804 aims to inhibit the suppressive immune receptor TIGIT, a checkpoint protein found on T cells and natural killer cells, facilitating improved ACT responses. The company incurred an income tax expense of $0.00 indicating its tax obligations, while the total costs and expenses for the company are $10,824,000.00 reflecting its overall spending. The gross profit ratio is 0.00 underscoring the efficiency of the company's production and sales operations. The net total of other income and expenses is -$2,000.00 reflecting non-core financial activities, and all financial data pertains to the fiscal year 2023. Phio Pharmaceuticals has established collaborations with AgonOx Inc. to advance the clinical development of novel T cell-based cancer immunotherapies. Formerly known as RXi Pharmaceuticals Corporation, the company underwent a name change to Phio Pharmaceuticals Corp. in November 2018 and is headquartered in Marlborough, Massachusetts. With a market capitalization of $6,209,905.00 the company is classified as a small-cap player in the biotechnology industry, contributing significantly to the overall market landscape. The stock is affordable at $1.29 making it suitable for budget-conscious investors. Nevertheless, it has a low average trading volume of 6,291,351.00 indicating lower market activity. The firm belongs to the Healthcare sector, driving innovation and growth within its field. As a key player in the Biotechnology industry, Phio Pharmaceuticals Corp. remains dedicated to advancing therapeutic solutions that enhance patient outcomes and address unmet medical needs in cancer treatment.
What is Phio Pharmaceuticals Corp. (PHIO)'s stock forecast?
Analysts predict Phio Pharmaceuticals Corp. stock to fluctuate between $1.22 (low) and $9.79 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Phio Pharmaceuticals Corp.'s market capitalization?
As of 2025-04-01, Phio Pharmaceuticals Corp.'s market cap is $6,209,905, based on 4,776,850 outstanding shares.
How does Phio Pharmaceuticals Corp. compare to competitors like Meta Platforms, Inc. Class A Common Stock?
Compared to Meta Platforms, Inc. Class A Common Stock, Phio Pharmaceuticals Corp. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Phio Pharmaceuticals Corp. (PHIO) stock?
To buy Phio Pharmaceuticals Corp. (PHIO) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for PHIO. Place an order (Market, Limit, etc.).
What is the best time to invest in Phio Pharmaceuticals Corp.?
The best time to invest depends on market trends and technical indicators, which show a Bullish trend based on economic conditions and company performance.
How did Phio Pharmaceuticals Corp. perform in the last earnings report?
Revenue: $0 | EPS: -$46.87 | Growth: -47.70%.
Where can I find Phio Pharmaceuticals Corp.'s investor relations reports?
Visit https://www.phiopharma.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Phio Pharmaceuticals Corp.?
You can explore historical data from here
What is the all-time high and low for Phio Pharmaceuticals Corp. stock?
All-time high: $470.88 (2021-02-18) | All-time low: $1.22 (2025-04-01).
What are the key trends affecting Phio Pharmaceuticals Corp. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
newsfilecorp.com
Interim Results from clinical study for cutaneous carcinomas presented at Late-Breaking Research Session Marlborough, Massachusetts--(Newsfile Corp. - March 10, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biotechnology company developing therapeutics that use its INTASYL® siRNA gene silencing technology designed to make the body's immune cells more effective in killing cancer cells. Phio today announced that a podium presentation addressing its lead product candidate, PH-762, was given in the Academy's Late-Breaking Research session.
newsfilecorp.com
Marlborough, Massachusetts--(Newsfile Corp. - March 5, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biotechnology company developing therapeutics that use its INTASYL® siRNA gene silencing technology designed to make the body's immune cells more effective in killing cancer cells. Phio announced today that it has fulfilled the required enrollment for safety in its third dose cohort in its Phase 1b dose escalating clinical study for their lead compound PH-762.
newsfilecorp.com
Registration Link for Presentation and live Q&A to take place, Wednesday March 5, 2025 at 12:00 pm EST Marlborough, Massachusetts--(Newsfile Corp. - February 26, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) a clinical-stage biotechnology company developing therapeutics that use its INTASYL® siRNA gene silencing technology designed to make the body's immune cells more effective in killing cancer cells. Phio announced today that Mr.
newsfilecorp.com
Marlborough, Massachusetts--(Newsfile Corp. - February 20, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biotechnology company developing therapeutics that use its INTASYL® siRNA gene silencing technology designed to make the body's immune cells more effective in killing cancer cells. Phio announced today the appointment of Mr.
newsfilecorp.com
Registration Link for Presentation and live Q&A to take place, Tuesday February 4, 2025 at 2:00 pm EST Marlborough, Massachusetts--(Newsfile Corp. - February 3, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biotechnology company developing therapeutics that use its INTASYL® siRNA gene silencing technology designed to make the body's immune cells more effective in killing cancer cells. Phio announced today that Mr.
newsfilecorp.com
Registration Link for Presentation and live Q&A to take place, Wednesday January 29, 2025 at 2:00 pm EST Marlborough, Massachusetts--(Newsfile Corp. - January 22, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biotechnology company developing therapeutics that use its INTASYL® siRNA gene silencing technology designed to make the body's immune cells more effective in killing cancer cells. Phio announced today that Mr.
newsfilecorp.com
Raised approximately $12.08 million in gross proceeds since beginning of December 2024 Proceeds intended to be directed for development costs to be incurred in connection with PH-762 clinical activities Marlborough, Massachusetts--(Newsfile Corp. - January 21, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage biotechnology company that develops therapeutics using its INTASYL® siRNA gene silencing technology to make the body's immune cells more effective in killing cancer cells, today announced the closing of its registered direct offering previously announced on January 16, 2024, priced at-the-market under Nasdaq rules, for the purchase and sale of an aggregate of 610,000 shares of its common stock at a purchase price of $3.00 per share. In addition, in a concurrent private placement, the Company issued short-term unregistered warrants to purchase up to an aggregate of 1,220,000 shares of common stock.
newsfilecorp.com
Marlborough, Massachusetts--(Newsfile Corp. - January 16, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage biotechnology company that develops therapeutics using its INTASYL® siRNA gene silencing technology to make the body's immune cells more effective in killing cancer cells, today announced that it has entered into definitive agreements for the purchase and sale of an aggregate of 610,000 shares of its common stock at a purchase price of $3.00 per share in a registered direct offering priced at-the-market under Nasdaq rules. In addition, in a concurrent private placement, the Company will issue short-term unregistered warrants to purchase up to an aggregate of 1,220,000 shares of common stock.
newsfilecorp.com
Marlborough, Massachusetts--(Newsfile Corp. - January 15, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage biotechnology company that develops therapeutics using its INTASYL® siRNA gene silencing technology to make the body's immune cells more effective in killing cancer cells, today announced that it has entered into definitive agreements for the purchase and sale of an aggregate of 833,335 shares of its common stock at a purchase price of $3.00 per share in a registered direct offering priced at-the-market under Nasdaq rules. In addition, in a concurrent private placement, the Company will issue short-term unregistered warrants to purchase up to an aggregate of 1,666,670 shares of common stock.
newsfilecorp.com
Marlborough, Massachusetts--(Newsfile Corp. - January 14, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage biotechnology company that develops therapeutics using its INTASYL® siRNA gene silencing technology to make the body's immune cells more effective in killing cancer cells, today announced that it has entered into definitive agreements for the purchase and sale of an aggregate of 1,063,670 shares of its common stock at a purchase price of $3.00 per share in a registered direct offering priced at-the-market under Nasdaq rules. In addition, in a concurrent private placement, the Company will issue short-term unregistered warrants to purchase up to an aggregate of 2,127,340 shares of common stock.
See all news
